InvestSMART

Biome Australia Limited (ASX:BIO)

ALERT: Price-sensitive ASX Announcement for BIO
Current share price for BIO : $0.265 -0.185 (-41.11%)+
Announcement
Release
2 Feb 2026 8:20AM
Price at Release
$0.450
Full Release
download
Summary
Biome Australia Limited has announced a significant expansion in the Canadian market by securing distribution for its range of Activated Probiotics through Fullscript, a leading practitioner distribution platform in North America. This strategic partnership, which complements Biome's existing collaboration with Ecotrend Ecologics, enables comprehensive market coverage, providing access to both traditional wholesale and digital dispensing channels. The Fullscript partnership is a critical step in Biome's Vision 27 strategy to establish itself as a global leader in evidence-based microbiome health, with operations extending to other key markets such as Ireland, New Zealand, and the UK.
Key Points
  • Biome Australia Limited secured distribution for its Canadian range through Fullscript, a major practitioner distribution platform in North America.
  • All Biome Activated Probiotics products are approved for launch on Fullscript Canada, with the launch planned for February 2026.
  • Fullscript serves over 100,000 healthcare practitioners and 5 million patients across North America.
  • The partnership with Fullscript complements Biome's existing relationship with Ecotrend Ecologics to cover the Canadian market comprehensively.
  • Fullscript partnership is a significant milestone in Biome's Canadian expansion strategy, facilitating access to practitione- to-patient supplement dispensing.
  • Biome Australia's Activated Probiotics are supported by clinical research and aim to improve health outcomes via practitioner channels.
  • The company is building scale across key markets including Canada, Ireland, New Zealand, and the UK as part of its Vision 27 international expansion strategy.
  • Biome Australia's partnership strategy in Canada ensures dual-channel coverage through both traditional wholesale and digital direct-to-patient dispensing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.